FDA creates new priority review voucher scheme to boost US interests
Pharmaceutical Technology
JUNE 18, 2025
The PRV programme for rare paediatric diseases, signed into law in 2012, expired in late 2024 after it failed to make it into a US Congress funding package. This effectively pushed the programme into its ‘sunsetting phase’. Give your business an edge with our leading industry insights.
Let's personalize your content